Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330
RBC Capital Reiterates Outperform on Ascendis Pharma, Maintains $290 Price Target
Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $356
Ascendis Pharma (NASDAQ:ASND) Offers Strong Growth With a Quality Technical Setup
Loading...